Pharmacy Times

It's here! The first issue of 'The Refill,' Pharmacy Times' new LinkedIn newsletter, is now available. Based on YOUR feedback, we're covering the updates that matter most: FDA recalls, infectious disease research, and breakthrough cancer treatments. Subscribe for your regular dose of pharmacy news! ? Check out Issue 1 and tell us: Which updates will impact your practice most?

Pharmacy technicians, previously limited to dispensing duties, are now empowered to administer vaccines under the supervision of a licensed pharmacist. With these new responsibilities comes the need for a clear understanding of the boundaries within which pharmacy technicians must operate, particularly regarding patient interaction and communication. Learn more: https://bit.ly/410QqDc

As social media’s popularity continues, integrating the use of platforms into pharmacy student education and advocacy for the field is essential, especially amid the decline of pharmacy student applications and graduating pharmacists. Learn more: https://bit.ly/3CCLJp0

The FDA approved bimekizumab-bkzx (Bimzelx; UCB) for the treatment of moderate-to-severe hidradenitis suppurativa (HS). The drug is the first and only approved medication that targets both interleukin (IL) 17F and IL-17A. Learn more: https://bit.ly/3OgocN8

The public seems to be transfixed by emerging information that psychedelic compounds (eg, lysergic acid diethylamide [LSD], methylenedioxymethamphetamine [MDMA], psilocybin) may have the potential to treat various mental health conditions safely and effectively when coupled with psychotherapy. Learn more: https://bit.ly/3Zc3Vyp

As health systems grapple with high turnover rates, understanding gaps in opportunities is crucial for implementing effective strategies to elevate technician practice, tackle deficits, bolster retention, and ensure a competent workforce capable of meeting escalating patient care demands. #pharmacytechnician Learn more: https://bit.ly/3CuHUSS

In #breaking news from #AHA24, #tirzepatide lowered the risk of worsening heart failure and CVD death in adults with #HFpEF and obesity. Learn more: https://ow.ly/4yc950U8xEs

The FDA granted regulatory approval to nilotinib tablets (Danziten; Azurity Pharmaceuticals), becoming the first and only nilotinib with no mealtime restrictions indicated for adults with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase, according to a news release from Azurity Pharmaceuticals. Learn more: https://bit.ly/48OszbT

The FDA approved eladocagene exuparvovec-tneq (Kebilidi; PTC Therapeutics Inc) for the treatment of adult and pediatric patients with aromatic L-amino acid decarboxylase (AADC) deficiency. Eladocagene exuparvovec-tneq is an adeno-associated virus vector-based gene therapy and became the first FDA-approved gene therapy for AADC deficiency. Learn more: https://lnkd.in/ebJE7kpc

The fight against scope creep—or provider status, known among pharmacists—is not new. Despite their proven abilities, organizations such as the American Medical Association still oppose so-called “scope creep." Learn more: https://lnkd.in/gQqBtkeD